Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis.
| العنوان: | Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis. |
|---|---|
| المؤلفون: | Ma BM; Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China., Tam AR; Division of Infectious Diseases, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China., Chan KW; Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China., Ma MKM; Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China., Hung IFN; Division of Infectious Diseases, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China., Yap DYH; Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China., Chan TM; Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China. |
| المصدر: | Frontiers in medicine [Front Med (Lausanne)] 2022 Mar 09; Vol. 9, pp. 827859. Date of Electronic Publication: 2022 Mar 09 (Print Publication: 2022). |
| نوع المنشور: | Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne, Switzerland : Frontiers Media S.A., [2014]- |
| مستخلص: | Background: Systematic data on the efficacy and safety of COVID-19 vaccine in patients on renal replacement therapy (RRT) remains limited. We conducted a meta-analysis on the efficacy and safety of COVID-19 vaccine in patients on RRT. Methods: Eligible studies were identified by systematic literature search in four electronic databases. Twenty-seven studies (4,264 patients) were included for meta-analysis. 99% patients received mRNA vaccine. Results: Patients on RRT showed inferior seropositivity after two-dosed COVID-19 vaccine, 44% lower than the general population. Kidney transplant recipients (KTRs) had significantly lower seropositivity than patients on haemodialysis (HD) or peritoneal dialysis (PD) (26.1 vs. 84.3% and 92.4% respectively, p < 0.001 for both). Compared with healthy controls, KTRs, HD and PD patients were 80% (95% CI: 62-99%), 18% (95% CI: 9-27%) and 11% (95% CI: 1-21%) less likely to develop antibodies after vaccination ( p < 0.001, <0.001 and 0.39 respectively). In KTRs, every 1% increase in using mycophenolate was associated with 0.92% reduction in seropositivity (95% CI: -1.68, -0.17, p = 0.021) at population level. The overall adverse event rate attributed to vaccination was 2.1%. Most events were mild. Conclusion: Patients on RRT, particularly KTRs, had significantly reduced antibody response after two-dosed COVID-19 vaccination. Vaccination is generally well tolerated. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42021261879. Competing Interests: DY received research donations from the Wai Im Charitable Foundation and the Chan Sui Kau Family Benefits and Charitable Foundation. DY and TM received research funding support from the Mr and Mrs Tam Wing Fun Edmund Renal Research Fund. TM also received research funding support from the Wai Hung Charitable Foundation and Mr. S. Ho. The donors have no role in the conduction of study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Ma, Tam, Chan, Ma, Hung, Yap and Chan.) |
| References: | Sci Immunol. 2021 Jun 15;6(60):. (PMID: 34131023) J Nephrol. 2020 Apr;33(2):343-354. (PMID: 31701375) Am J Nephrol. 2010;31(3):247-54. (PMID: 20090311) Clin Infect Dis. 2021 Sep 19;:. (PMID: 34537835) Nephrol Dial Transplant. 2021 Aug 27;36(9):1704-1709. (PMID: 34057463) Hum Vaccin Immunother. 2021 Sep 2;17(9):2873-2893. (PMID: 34033528) Am J Transplant. 2021 Aug;21(8):2913-2915. (PMID: 33864722) Lancet. 2021 Dec 19;396(10267):1979-1993. (PMID: 33220855) Nephrol Dial Transplant. 2021 Aug 27;36(9):1754-1755. (PMID: 34450648) J Am Soc Nephrol. 2021 Sep;32(9):2153-2158. (PMID: 34135083) JAMA. 2021 Jun 1;325(21):2204-2206. (PMID: 33950155) Kidney Int. 2021 Aug;100(2):476-477. (PMID: 34081947) J Clin Invest. 2021 Jul 15;131(14):. (PMID: 34101623) J Am Soc Nephrol. 2021 Oct;32(10):2435-2438. (PMID: 34117129) J Am Soc Nephrol. 2021 Nov;32(11):2735-2742. (PMID: 34348908) Mil Med Res. 2020 Feb 29;7(1):7. (PMID: 32111253) N Engl J Med. 2021 Aug 12;385(7):661-662. (PMID: 34161700) Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4. (PMID: 33957273) Clin Kidney J. 2021 Jun 11;14(9):2127-2128. (PMID: 34471524) Kidney Int. 2021 Jun;99(6):1496-1498. (PMID: 33887318) J Am Soc Nephrol. 2021 Oct 1;:. (PMID: 34599041) Nephrol Dial Transplant. 2021 Apr 11;:. (PMID: 33839785) Lupus. 2005;14 Suppl 1:s2-8. (PMID: 15803924) Clin Infect Dis. 2021 Jul 15;73(2):e304-e311. (PMID: 32556176) Kidney Int. 2021 Jun;99(6):1490-1492. (PMID: 33887317) Am J Transplant. 2021 Aug;21(8):2727-2739. (PMID: 34036720) Transplantation. 2021 Sep 1;105(9):e94-e95. (PMID: 33831941) Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463) Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716. (PMID: 33999200) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Syst Rev. 2015 Jan 01;4:1. (PMID: 25554246) Clin J Am Soc Nephrol. 2021 Jul;16(7):1037-1042. (PMID: 33824157) N Engl J Med. 2020 Dec 17;383(25):2427-2438. (PMID: 32991794) Ann Intern Med. 2021 Sep;174(9):1336-1338. (PMID: 34029487) JAMA Intern Med. 2022 Feb 1;182(2):165-171. (PMID: 34928302) Clin J Am Soc Nephrol. 2021 Aug;16(8):1258-1260. (PMID: 34031182) Clin J Am Soc Nephrol. 2021 Jul;16(7):1073-1082. (PMID: 34031181) Transplantation. 2021 Oct 1;105(10):2170-2174. (PMID: 33859151) J Am Soc Nephrol. 2021 May 3;32(5):1033-1036. (PMID: 33637518) Am J Nephrol. 2008;28(4):654-60. (PMID: 18322360) Vaccines (Basel). 2021 Apr 08;9(4):. (PMID: 33918085) JAMA. 2020 May 12;323(18):1824-1836. (PMID: 32282022) Viruses. 2021 Apr 25;13(5):. (PMID: 33923063) Am J Transplant. 2021 Aug;21(8):2719-2726. (PMID: 33866672) Kidney Int. 2021 Jun;99(6):1487-1489. (PMID: 33775674) Nat Rev Nephrol. 2013 May;9(5):255-65. (PMID: 23507826) Med Sci Monit. 2013 Nov 18;19:1013-8. (PMID: 24241247) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) N Engl J Med. 2021 May 13;384(19):1824-1835. (PMID: 33440088) |
| فهرسة مساهمة: | Keywords: COVID-19; chronic kidney disease; immunogenicity; safety; vaccine |
| تواريخ الأحداث: | Date Created: 20220331 Latest Revision: 20220401 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8959490 |
| DOI: | 10.3389/fmed.2022.827859 |
| PMID: | 35355604 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2296-858X |
|---|---|
| DOI: | 10.3389/fmed.2022.827859 |